Antihypertensive monotherapy is often insufficient to control blood pressure (BP).
require more than two drugs to achieve BP control. 5 Therefore, major hypertension treatment guidelines currently suggest that combination antihypertensive therapy be used initially, particularly for high-risk patients or those with very high baseline BP. 2, 4 For the general population (all ages, including patients with diabetes mellitus but not CKD), JNC 8 specifically recommends that combination therapy be initiated with two drugs simultaneously (either as two separate pills or as a single-pill combination) if systolic BP is >160 mm Hg and/or diastolic BP is >100 mm Hg, or if systolic BP is >20 mm Hg above goal and/or diastolic BP is >10 mm Hg above goal. 2 Ongoing clinical trials, along with updated societal guidelines and meta-analyses of previously published studies, will continue to shape hypertension treatment recommendations in the future.
A large body of clinical trial data has demonstrated that the ARB olmesartan medoxomil (OM) is well tolerated and effective in reducing BP. OM has been shown to provide 24-hour BP-lowering coverage and has a safety profile similar to that of placebo when used as monotherapy or in combination therapy, 6 including when used across a wide range of patient subgroups (obese, elderly, children, black, Hispanic, or those with diabetes mellitus). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In light of the various recommendations from treatment guidelines and clinical trials, the current metaanalysis sought to compare the efficacy and safety of OM single-pill dual-combination therapy with that of OM monotherapy. Analyses were performed in the following subgroups of patients with hypertension: elderly, nonelderly, CKD, and non-CKD.
| MATERIALS AND METHODS

| Database definition and inclusion criteria
An integrated database of previously locked individual OM clinical Studies were included if they met the following criteria: randomized, double-blind, placebo-or active-controlled, phase 2 through 4 clinical trials and a scheduled double-blind treatment duration of ≥28 days for the entire period of parallel design or for the first crossover period.
To be included in the meta-analysis, the studies had to have a doubleblind period of at least 8 weeks including patients (aged ≥18 years) with hypertension in which randomized treatment consisted of either OM single-pill dual-combination therapy with amlodipine, azelnidipine, or hydrochlorothiazide compared with OM monotherapy, and have evaluated BP-lowering efficacy and BP goal achievement end points ( Figure S1 ). Institutional review boards reviewed and approved study protocols per local regulations, and patients provided written informed consent for each individual study included in the meta-analysis.
| Assessments
Efficacy end points that were studied included mean seated BP (SeBP;
included seated systolic BP [SeSBP] and seated diastolic BP) and change from baseline in mean SeBP at each time point (observed case approach) and end point (week 8; last-observation-carried-forward
[LOCF] approach); and the proportion of patients achieving mean SeBP <140/90 mm Hg and SeSBP <140 mm Hg at end point (LOCF approach).
Comprehensive safety assessments reported the incidence of any treatment-emergent adverse event (TEAE) occurring within the first 8 weeks of the double-blind period or until permanent discontinuation of study medication, whichever occurred first, including those that were drug-related or serious, the number of deaths, and the incidence of individual TEAEs.
| Statistical analysis
The primary statistical analysis was based on the full analysis set, defined as all patients who received at least one dose of study medication and had a nonmissing baseline and at least one nonmissing postbase- 
| RESULTS
| Baseline characteristics
The integrated database consisted of 53 trials completed between 1996 and 2012 and represented 34 320 patients. Seven studies were included in the meta-analysis according to the inclusion criteria previously stated ( Figure S1 and Table S1 ). 10, [17] [18] [19] [20] [21] The full analysis set comprised 5888 patients (OM dual-combination therapy group, n = 3969; OM monotherapy group, n = 1919). Apparent differences between the baseline characteristics of the OM dual-combination therapy and OM monotherapy groups were small ( Abbreviations: BMI, body mass index; CHD, coronary heart disease; CKD, chronic kidney disease; dual, dual therapy; eGFR, estimated glomerular filtration rate; HF, heart failure; mono, monotherapy; OM, olmesartan medoxomil; SeDBP, seated diastolic blood pressure; SeSBP, seated systolic blood pressure.
a Based on the Modification of Diet in Renal Disease formula.
and patients with CKD whose mean baseline SeSBP values were slightly higher ( Table 1 ). The rates of diabetes mellitus and high cardiovascular risk were higher among elderly patients compared with nonelderly patients. Similarly, compared with patients without CKD, the subgroup of patients with CKD had a higher incidence of diabetes mellitus, coronary heart disease, heart failure, and high cardiovascular risk.
| Efficacy
| Full analysis set
In the full analysis set, mean SeBP decreased rapidly towards the 
| Elderly and nonelderly subgroups
The Figure   S4C ), both in favor of OM dual-combination therapy. Supplementary analysis using a revised threshold for elderly patients (aged ≥70 years) was performed to examine the effect of treatment in the older group.
Baseline SeBP, mean SeBP change from baseline, and the proportion of patients achieving a BP goal of <140/90 mm Hg were similar between the ≥60-and ≥70-year age thresholds (Table S2) .
| CKD and non-CKD subgroups
Of all patients in the full analysis set, 642 had CKD (OM dual-combination therapy, n = 428; OM monotherapy, n = 214) and 5245 patients were assigned to the non-CKD subgroup (OM dual-combination therapy, n = 3540; OM monotherapy, n = 1705). At study end, mean SeBP was lower among patients receiving OM dual-combination therapy com- 
| BP goal achievement
While none of the trials were randomized to two different BP goals and evaluated cardiovascular outcomes, most studies in the integrated database targeted an SeBP goal of <140/90 mm Hg during the double-blind treatment period (Table S1 ). In the full analysis set, 
| Safety
| Full analysis set
The proportion of patients experiencing any TEAE was comparable between the OM dual-combination therapy and OM monotherapy 
| Elderly and nonelderly subgroups
In the elderly subgroup, the incidence of any TEAE was lower in the OM dual-combination therapy group than in the OM monotherapy group (28.3% vs 32.2%, respectively) ( Table 2 ). The incidence of serious TEAEs and drug-related TEAEs was similar between treatment groups. More elderly than nonelderly patients experienced a TEAE with OM monotherapy (32.2% vs 28.3%, respectively). The incidence of any TEAE was similar between elderly and nonelderly subgroups for patients treated with OM dual-combination therapy (28.3% vs 29.1%, respectively) ( Table 2 ). Among the most frequently observed TEAEs in the full analysis set, there were no noticeable trends or differences when comparing treatment groups in the elderly vs nonelderly subgroups, with the exception of back pain with OM monotherapy (2.2% vs 0.8%, respectively).
| CKD and non-CKD subgroups
In the CKD subgroup, the incidence of any TEAE was higher in the OM monotherapy group than in the OM dual-combination therapy group (39.7% vs 32.9%, respectively) ( Table 2 ). The incidence of serious TEAEs was similar between subgroups receiving monotherapy or dualcombination therapy. Compared with the non-CKD subgroup, the incidence of any TEAE and any drug-related TEAE was higher in the CKD subgroup ( Table 2 ). More patients experienced peripheral edema and edema in the CKD subgroup vs the non-CKD subgroup, regardless of the treatment received ( Table 2 ).
| DISCUSSION
Hypertension guidelines generally recommend starting patients with hypertension on monotherapy, with treatment options including angiotensin-converting enzyme inhibitors, ARBs, calcium channel blockers, thiazide-type diuretics, or a β-blocker. Guidelines such as those from ASH/ISH provide advice on specific drug selection by patient type. 3 If the initial treatment is not sufficient to achieve BP goals, patients may be prescribed a higher dose of monotherapy up to a maximum dose or will need a second agent from a different drug class added to the initial drug choice. Most patients are unable to achieve BP goals with monotherapy alone, and combination therapy with two or more agents may be necessary to achieve recommended BP goals. 5 The current meta-analysis examined the efficacy and safety of OM dual-combination therapy vs OM monotherapy to provide further information on whether initiating hypertension management with combination therapy may be the preferred treatment approach for patients with hypertension. started on combination therapy were more likely to achieve BP goals after 12 months of therapy compared with patients who had started on monotherapy. 23 In light of these findings, initiating antihypertensive treatment with combination therapy may be preferred over initiating treatment with a single agent alone.
The prevalence of hypertension increases with age, being present in 65% of patients 60 years and older and in 76.5% of patients T A B L E 2 TEAEs reported by ≥1% of patients in the OM monotherapy and single-pill dual-combination therapy groups for the full analysis set and elderly, nonelderly, CKD, and non-CKD subgroups Abbreviations: CKD, chronic kidney disease; dual, dual therapy; mono, monotherapy; OM, olmesartan medoxomil; TEAE, treatment-emergent adverse event.
a By preferred term and primary system organ class.
80 years and older. 24 The ESH/ESC guidelines recommend the use of diuretics and calcium channel blockers for treating isolated systolic hypertension in the elderly. 4 In this meta-analysis, elderly patients aged Hypertension and CKD are closely related conditions. 25 The prevalence of hypertension is even greater among patients with CKD than in the general population. 26 Consistent with the results observed in the full analysis set, OM dual-combination therapy was associated with greater improvements than OM monotherapy among patients with and without CKD. However, the magnitude of treatment response was smaller in the CKD vs the non-CKD subgroup, and a smaller proportion of patients with CKD achieved BP goals.
11
A previous meta-analysis by Wang and colleagues 27 showed no association between OM and an increased risk of adverse events 
| STUDY STRENGTHS AND LIMITATIONS
A major strength of this meta-analysis was the large sample size of patients in the full analysis set and elderly/nonelderly subgroups taken from pooled randomized controlled trials. While the definition of elderly used in this analysis (aged ≥60 years) differs from some organizational guidelines, supplemental analyses examining an alternative definition of elderly (aged ≥70 years) suggested little difference in the efficacy of OM dual-combination or monotherapy. A limitation to this meta-analysis was the short duration of the study, which was not extensive enough to identify rare serious adverse events.
| CONCLUSIONS
In this patient-level meta-analysis of randomized, double-blind, placebo-or active-controlled, phase 2 to 4 clinical trials in patients with hypertension, OM single-pill dual-combination therapy was well tolerated and more effective in lowering BP than OM monotherapy, enabling more patients to achieve guideline-recommended BP goals with a preferable safety profile.
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